News | August 29, 2025
Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Guidelines aim to establish state-regulated veterinary blood banks
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Subscribe To Our Newsletter & Stay Updated
